SOURCE: Corporate Profile LLC

Corporate Profile LLC

April 14, 2010 12:49 ET

Rexahn Update by Goldman Small Cap Research Issued on Corporate Profile's

NEW YORK NY--(Marketwire - April 14, 2010) - Corporate Profile's newest financial website, announces an Update. Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, has issued a research update on Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best-in-class oncology and CNS therapeutics. See update at or

In the Goldman Select Research report on the Company, analyst Rob Goldman outlines his thesis for what he describes as a buying opportunity following the recent sell-off.

 "In our view, the trial results were a great success, not a failure, as indicated by some news outlets. In fact, the results showed significant improvement in patients with severe Major Depressive Disorder with fewer side effect complaints than those in placebo. We think the unwarranted sell-off creates a unique buying opportunity and that investors have forgotten Rexahn is not a one-trick pony. The Company has a slew of good news pending this quarter and we maintain our belief that a Big Pharma partner for Serdaxin is in the offing," stated Rob Goldman.

About Corporate Profile LLC
The Corporate Profile® network, a rapidly expanding website group is focused on the intersection of finance, fashion and lifestyle. 

About a Corporate Profile®  website and newsletter provides readers and subscribers fresh, original, and highly informative ideas and market commentary that they won't get anywhere else. Content is focused on what is going on in the stock market and on Wall Street, including stories about large-capitalization as well as small-cap companies, both on the long and short side.

About Goldman Small Cap Research

Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces stock market research reports. The Firm produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select product reflects the Firm's internally generated stock ideas while the Opportunity product reflects sponsored research reports. While performance is tracked separately, the same coverage criteria are utilized in determining coverage of all stocks in both research formats. For more information and to view report in its entirety, visit

About Rexahn Pharmaceuticals

 Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN) is a clinical stage pharmaceutical company dedicated to commercializing first in class and market leading therapeutics for cancer, CNS (Central Nervous System) disorders, sexual dysfunction and other unmet medical needs. Rexahn currently has three drug candidates in Phase II clinical trials, Archexin™, Serdaxin®, and Zoraxel™ - all potential best in class therapeutics - and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders. Rexahn also operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery platforms.